Advanced Oncotherapy (AVO) – Holdings in company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights An acquisition or disposal of qualifying financial instruments which may […]

Advanced Oncotherapy (AVO) – Holdings in company

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES 1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii 2 Reason for the notification (please tick the appropriate box or boxes): An acquisition or disposal of voting rights   √   An acquisition or disposal of qualifying financial […]

Advanced Oncotherapy (AVO) – Update on Bracknor financing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that further to the notification on 22 February 2017, the Company has drawn down the second tranche of £1.3 million (less 5%, in accordance with terms for receipt of 95% of nominal value of each tranche). Proceeds will continue to […]

Advanced Oncotherapy (AVO) – Executive Chairman buys 200,000 shares

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that, yesterday, Dr Mike Sinclair purchased 200,000 Ordinary Shares of 25 pence in the Company at an average price of 30.44 pence per Ordinary Share. Following this transaction, Dr Sinclair now holds 4,928,229 Ordinary Shares, representing 6.65% of the issued […]

Advanced Oncotherapy (AVO) – Conversion of Convertible Loan Notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that Bracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of […]

Advanced Oncotherapy (AVO) – Additional financing agreement

Advanced Oncotherapy plc (AIM: AVO), the developer of next generation proton therapy systems for cancer treatment, announces that on Tuesday 25 April it drew down a further £2 million as part of the 12-month convertible and redeemable loan agreement announced on 27 March 2017 with Blackfinch Investment Ltd, through its subsidiary Henslow Trading Limited. This […]

Advanced Oncotherapy (AVO) – Director Dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 26.96 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,123,946 Ordinary Shares, representing 1.52% of the issued share […]

Advanced Oncotherapy (AVO) – Conversion of loan notes

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces thatBracknor Investment Group has advised the Company that they will convert a portion of the first tranche of the Convertible Loan Notes issued to them on 22 February 2017 into new ordinary shares of 25p each in the share capital of […]

Advanced Oncotherapy (AVO) – Director dealing

Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that yesterday, Dr Enrico Vanni purchased 100,000 Ordinary Shares of 25 pence in the Company at a price of 27.5 pence per Ordinary Share. Following this transaction, Dr Vanni now holds 1,023,946 Ordinary Shares, representing 1.40% of the issued share […]